Interferon alfa-2b in the treatment of chronic myelogenous leukemia.
Thirty-six patients with Philadelphia chromosome-positive CML were treated with interferon alfa-2b for at least 3 months. Thirty-two of the patients had chronic phase disease and four had acute phase disease, one in blast crisis. Patients initially received a daily dose of 4 megaunits/m2 administered subcutaneously; outpatient self administration followed at a dosage decreased in accordance with serially determined blood cell counts. Treatment was continued for 0.5 to 15 months, with a median duration of 7 months. No complete remission was achieved, but hematologic remission occurred in 21 (58%) patients, with partial hematologic remission in an additional 12 (33%). All four patients with acute phase disease failed to respond. Adverse reactions were only significant during the first days of treatment and did not interfere with self administration of the drug. Interferon alfa-2b may prove to be an important alternative therapeutic modality in chronic phase CML.
Niederle
N
N
Kloke
O
O
Osieka
R
R
Wandl
U
U
Opalka
B
B
Schmidt
C G
CG
D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000097:blood / Q000628:therapy*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011994:Recombinant Proteins / Q000627:therapeutic use
D007370:Interferon Type I; D011994:Recombinant Proteins